Northern Trust’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-383,323
| Closed | -$7.11M | – | 4603 |
|
|
2023
Q3 | $7.11M | Buy |
383,323
+106,216
| +38% | +$1.2M | ﹤0.01% | 2223 |
|
|
2023
Q2 | $3.06M | Buy |
277,107
+4,915
| +2% | +$68.5K | ﹤0.01% | 2771 |
|
|
2023
Q1 | $3.66M | Buy |
272,192
+3,197
| +1% | +$55.3K | ﹤0.01% | 2641 |
|
|
2022
Q4 | $3.33M | Buy |
268,995
+20,980
| +8% | +$297K | ﹤0.01% | 2719 |
|
|
2022
Q3 | $3.46M | Sell |
248,015
-592
| -0.2% | -$9.53K | ﹤0.01% | 2709 |
|
|
2022
Q2 | $3.43M | Sell |
248,607
-16,155
| -6% | -$259K | ﹤0.01% | 2752 |
|
|
2022
Q1 | $4.31M | Sell |
264,762
-13,385
| -5% | -$210K | ﹤0.01% | 2667 |
|
|
2021
Q4 | $4.53M | Sell |
278,147
-7,057
| -2% | -$119K | ﹤0.01% | 2744 |
|
|
2021
Q3 | $4.24M | Sell |
285,204
-15,003
| -5% | -$240K | ﹤0.01% | 2836 |
|
|
2021
Q2 | $6M | Buy |
300,207
+13,866
| +5% | +$275K | ﹤0.01% | 2735 |
|
|
2021
Q1 | $6.61M | Sell |
286,341
-12,190
| -4% | -$340K | ﹤0.01% | 2565 |
|
|
2020
Q4 | $7.37M | Sell |
298,531
-8,895
| -3% | -$295K | ﹤0.01% | 2448 |
|
|
2020
Q3 | $12.7M | Sell |
307,426
-34,341
| -10% | -$1.58M | ﹤0.01% | 1946 |
|
|
2020
Q2 | $16.4M | Buy |
341,767
+6,564
| +2% | +$507K | ﹤0.01% | 1776 |
|
|
2020
Q1 | $21.1M | Buy |
335,203
+3,566
| +1% | +$320K | 0.01% | 1355 |
|
|
2019
Q4 | $41.1M | Sell |
331,637
-3,180
| -0.9% | -$285K | 0.01% | 1157 |
|
|
2019
Q3 | $22.2M | Buy |
334,817
+41,041
| +14% | +$2.76M | 0.01% | 1606 |
|
|
2019
Q2 | $23.4M | Buy |
293,776
+23,309
| +9% | +$2.09M | 0.01% | 1567 |
|
|
2019
Q1 | $30.3M | Buy |
270,467
+4,806
| +2% | +$525K | 0.01% | 1364 |
|
|
2018
Q4 | $26.8M | Sell |
265,661
-1,720
| -0.6% | -$178K | 0.01% | 1328 |
|
|
2018
Q3 | $33.8M | Buy |
267,381
+9,626
| +4% | +$1.02M | 0.01% | 1348 |
|
|
2018
Q2 | $21.6M | Buy |
257,755
+168,955
| +190% | +$12.4M | 0.01% | 1723 |
|
|
2018
Q1 | $5.46M | Buy |
88,800
+2,489
| +3% | +$150K | ﹤0.01% | 2524 |
|
|
2017
Q4 | $5.04M | Buy |
86,311
+182
| +0.2% | +$11.5K | ﹤0.01% | 2601 |
|
|
2017
Q3 | $5M | Buy |
86,129
+1,146
| +1% | +$123K | ﹤0.01% | 2639 |
|
|
2017
Q2 | $10.3M | Buy |
84,983
+10,993
| +15% | +$1.27M | ﹤0.01% | 2163 |
|
|
2017
Q1 | $8.37M | Sell |
73,990
-6,993
| -9% | -$816K | ﹤0.01% | 2241 |
|
|
2016
Q4 | $8.8M | Buy |
80,983
+4,489
| +6% | +$535K | ﹤0.01% | 2197 |
|
|
2016
Q3 | $12.6M | Buy |
76,494
+2,640
| +4% | +$416K | ﹤0.01% | 1908 |
|
|
2016
Q2 | $10.5M | Buy |
73,854
+2,570
| +4% | +$375K | ﹤0.01% | 1990 |
|
|
2016
Q1 | $9.4M | Buy |
71,284
+3,188
| +5% | +$376K | ﹤0.01% | 2015 |
|
|
2015
Q4 | $10.2M | Sell |
68,096
-4,356
| -6% | -$737K | ﹤0.01% | 2005 |
|
|
2015
Q3 | $12M | Buy |
72,452
+17,303
| +31% | +$3.81M | ﹤0.01% | 1857 |
|
|
2015
Q2 | $13.3M | Buy |
55,149
+2,191
| +4% | +$583K | ﹤0.01% | 1873 |
|
|
2015
Q1 | $14.9M | Buy |
52,958
+5,767
| +12% | +$1.25M | ﹤0.01% | 1795 |
|
|
2014
Q4 | $7.36M | Sell |
47,191
-781
| -2% | -$144K | ﹤0.01% | 2244 |
|
|
2014
Q3 | $11.4M | Sell |
47,972
-53,249
| -53% | -$13.6M | ﹤0.01% | 1943 |
|
|
2014
Q2 | $24M | Sell |
101,221
-13,870
| -12% | -$3.66M | 0.01% | 1372 |
|
|
2014
Q1 | $38M | Buy |
115,091
+7,626
| +7% | +$2.57M | 0.01% | 1036 |
|
|
2013
Q4 | $7.34M | Buy |
107,465
+10,351
| +11% | +$598K | ﹤0.01% | 2294 |
|
|
2013
Q3 | $6.7M | Buy |
97,114
+21,761
| +29% | +$1.07M | ﹤0.01% | 2303 |
|
|
2013
Q2 | $3.38M | Buy |
+75,353
| New | +$2.57M | ﹤0.01% | 2667 |
|
Northern Trust's ICPT Position: Q4 2023 in Review
Northern Trust sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 383,323 shares — an estimated $7.11M sold.
Northern Trust first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $41.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Northern Trust reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Northern Trust sold 383,323 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $7.11M.
- Northern Trust first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Northern Trust's Intercept Pharmaceuticals, Inc. position peaked at $41.1M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Northern Trust's 13F filing for Q4 2023, filed 13 Feb 2024.